Roche Drug Scores Label Expansion for Earlier Use in Lung Cancer
The FDA expanded the approval of Roche’s Alecensa to include adjuvant treatment of non-small cell lung cancer. The targeted therapy addresses cancers driven by the ALK genetic mutation.